Monoclonal antiidiotypic antibodies neutralize cytotoxic effects of anti-αGal antibodies

Transplantation

Volumn 62, Issue 6, 1996, Pages 837-843

  Koren, Eugen ^a,c   Milotic, Franko ^a   Neethling, Francisca A ^b   Koscec, Mirna ^a   Fei, David ^c   Kobayashi, Takaaki ^b   Taniguchi, Shigeki ^b   Cooper, David K C ^b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b INTEGRIS Nazih Zuhdi Transplant Institute   (United States)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ANTIPIG; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; BABOON; CYTOTOXICITY; DIAGNOSIS; FEMALE; GRAFT REJECTION; HYBRIDOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029742923     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199609270-00023     Document Type: Article

References (33)

1. Calne RY. Organ transplantation between widely disparate species. Transplant Proc 1970; 2: 550.
2. Rose AG, Cooper DKC, Human PA, et al. Histopathology of hyperacute rejection of the heart: experimental and clinical observations in allografts and xenografts. J Heart Lung Transplant 1991; 10: 223.
3. Rosenberg JC, Hawkins E, Rector F. Mechanisms of immunological injury during antibody-mediated hyperacute rejection of renal heterografts. Transplantation 1971; 11: 151.
4. Hammer C, Chaussey CH, Brendel W. Preformed natural antibodies in animals and man: Outlook on xenotransplantation. Eur Surg Res 1973; 5: 162.
5. Paul LC. Mechanism of humoral xenograft rejection. In: Cooper DKC, et al. (eds). Xenotransplantation. Heidelberg: Springer, 1991: 47.
6. Platt JL, Bach FH. Mechanism of tissue injury in hyperacute xenograft rejection. In: Cooper DKC, et al. (eds). Xenotransplantation. Heidelberg, Springer, 1991: 69.
7. Cooper DKC, Ye Y, Rolf LL Jr, Zuhdi N. The pig as potential donor for man. In: Cooper DKC, et al. (eds). Xenotransplantation. Heidelberg, Springer, 1991: 481.
8. Good AH, Cooper DKC, Malcolm AJ, et al. Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xengrafting in humans. Transplant Proc 1992; 24: 559.
9. Cooper DKC, Good AH, Koren E, et al. Identification of α-galactosyl and other carbohydrates that are bound by human anti-pig antibodies: relevance to discordant xenografting in man. Transplant Immunol 1993; 1: 198.
10. Galili U, Rachmilewitz EA, Peleg A, et al. A unique natural human IgG antibody with anti-α-galactosyl specificity. J Exp Med 1984; 260: 1519.
11. Kujundzic M, Koren E, Neethling FA, et al. Variability of anti-αGal antibodies in human serum and their relation to serum cytotoxicity against pig cells. Xenotransplantation 1994; 1: 58.
12. Cooper DKC, Ye Y, Kehoe M, et al. A novel approach to "neutralization" of preformed antibodies: cardiac allotransplantation across the ABO-blood group barrier as a paradigm of discordant xenotransplantation. Transplant Proc 1992; 24: 566.
13. Cooper DKC, Ye Y, Niekrasz M, et al. Specific intravenous carbohydrate therapy - a new concept in inhibiting antibody-mediated rejection: experience with ABO-incompatible cardiac allografting in the baboon. Transplantation 1993; 56: 769.
14. Bannett AD, McAlack RF, Raja R, Baquero A, Morris M. Experiences with known ABO-mismatched renal transplants. Transplant Proc 1987; 19: 4543.
15. Cooper DKC, Koren E, Oriol R. Genetically engineered pigs. Lancet 1993; 342: 682.
16. Cooper DKC, Koren E, Oriol R. Oligosaccharides and discordant xenotransplantation. Immunol Rev 1994; 141: 31.
17. Cooper DKC, Koren E. Genetically engineered animals for use as organ donors. USSN 1993; 08/049: 817.
18. Cooke A. Regulation of the immune response. In: Roitt I, et al. (eds). Immunology. London, Mosby-Year Book, 1993: 94.
19. Goding JW. Production of monoclonal antibodies. In: Goding JW. Monoclonal antibodies: principles and practice. London, Academic, 1986: 71.
20. Koren E, Kujundzic M, Koscec M, et al. Cytotoxic effects of human preformed anti-Gal IgG and complement on cultured pig cells. Transplant Proc 1994; 26: 1336.
21. Koren E, Solter D, Lee DM, et al. Characterization of monoclonal antibody that binds equally to all apolipoprotein and lipoprotein forms of human plasma apolipoprotein B: Specificity and binding studies. Biochim Biophys Acta 1986; 876: 91.
22. Miyajima T, Higuchi R, Kashiwabara H, Yokoyama T, Fujimoto S. antiidiotypic antibodies in a patient with a functioning renal graft. Nature 1980; 283: 306.
23. Pohanka E, Manfro RC, Oto C, et al. antiidiotypic antibodies to HLA after donor-specific blood transfusion (DST). Transplant Proc 1989; 21: 1806.
24. Reed E, Hardy M, Benvenisty A, et al. Effect of antiidiotypic antibodies to HLA on graft survival in renal allograft recipients. N Engl J Med 1987; 316: 1450.
25. Rodey GA, Phelan DL. Association of antiidiotypic antibody with successful second transplant of a kidney sharing HLA antigens with the previous hyperacutely rejected first kidney. Transplantation 1989; 48: 54.
26. Kobayashi T, Taniguchi S, Ye Y, et al. Delayed xenograft rejection in C3-depleted (pig-to-baboon) cardiac xenografts treated with cobra venom factor. Presented at the Third International Congress for xenotransplantation, Boston, 1995. Transplant Proc (in press).
27. Kobayashi T, Taniguchi S, Ye Y, et al. Delayed xenograft rejection in C3-depleted (pig-to-baboon) cardiac xenografts treated with cobra venom factor. Presented at the Third International Congress for xenotransplantation, Boston, 1995. Transplant Proc (in press).
28. Adair JR. Engineering antibodies for therapy. Immunol Rev 1992; 130: 5.
29. Jolliffe LK. Humanized antibodies: enhancing therapeutic utility through antibody engineering. Int Rev Immunol 1993; 10: 241.
30. Woodle ES, Thistlewaite JR, Jolliffe LK, et al. Humanized antibodies: successful transfer of immune modulating properties and idiotype expression. J Immunol 1992; 148: 2756.
31. Ghetie V, Swindell E, Uhr JW, Vitetta ES. Purification and properties of immunotoxins containing one vs. two deglycosylated ricin A chains. J Immunol Methods 1993; 166: 117.
32. Amlot PL, Stone MJ, Cunningham D, et al. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 1993; 82: 2624.
33. Grossbard ML, Gribben JG, Freedman AS, et al. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 1993; 81: 2263.